Tubeless VATS for Mediastinal Neoplasm

Launched by SHUBEN LI · Jul 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to perform surgery to remove tumors located in the middle part of the chest, called the mediastinum. Usually, such surgeries use a breathing tube and general anesthesia, but this trial is testing a technique called “tubeless” video-assisted thoracoscopic surgery (VATS), which uses a less invasive form of anesthesia without placing a breathing tube. The goal is to see if this method is safe and if it helps patients recover better after surgery.

Adults between 18 and 80 years old who have a tumor smaller than 6 centimeters in the mediastinum, confirmed by a CT scan, may be eligible to join. To participate, patients need to be in reasonably good health (based on a standard health assessment) and able to understand the study and give consent. People with tumors that have spread to nearby organs or with serious heart problems or other active cancers cannot join. If you take part, you can expect to have surgery using this less invasive anesthesia approach, and the doctors will carefully monitor how well it works and how it affects recovery. This study is currently recruiting patients and aims to find out if this tubeless method is a safe and effective option for mediastinal tumor surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Mediastinal neoplasm was diagnosed by chest enhanced CT
• • 2. The patients with age ≥ 18 and ≤ 80 years old
• • 3. The patients whose tumor diameter was \<6 cm
• • 4. ASA grade: I-III
• • 5. The patients should understand the research and sign the informed consent
• Exclusion Criteria:
• • 1. Imaging examinations revealed that the tumor had invaded adjacent organs, with evidence of pleural or pericardial dissemination, as well as lymphatic and/or hematogenous metastases
• • 2. Patients with a confirmed history of congestive heart failure, poorly controlled angina despite medical therapy, electrocardiogram-confirmed myocardial infarction with transmural involvement, uncontrolled hypertension, clinically significant valvular heart disease, or high-risk arrhythmias not adequately managed
• • 3. Patients with concurrent active malignancies